ArticleJournal of clinical and translational science2023
A community-partnered approach for diversity in COVID-19 vaccine clinical trials.
Article in Journal of clinical and translational science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 14 citations in OpenAlex.
- More than a moment: Evolving decisions among eligible volunteers in phase 1 COVID-19 vaccine trials.Human vaccines & immunotherapeutics · 2026Article
- "It's Like Disrupting Internally:" a Qualitative Study of Opportunities and Limitations to Promote Diversity in Participant Recruitment in Health Research.Journal of racial and ethnic health disparities · 2026Article
- Detecting and Mitigating Bias for Inclusive and Trustworthy Clinical Research: A Scientific Statement From the American Heart Association.Circulation. Genomic and precision medicine · 2026Review
- Designing communication strategies to increase rural participation in clinical trials using the Health Belief Model and strategic communication.Contemporary clinical trials communications · 2026Article
- PEARLES challenges and solutions to the implementation of clinical research responses to epidemics and pandemics: a scoping review.EClinicalMedicine · 2025Review
- Recruiters' lived experiences in COVID-19 vaccine trials in eThekwini, KwaZulu-Natal.Health SA = SA Gesondheid · 2025Article
- COVID-19 clinical trial participation and awareness in Texas.Human vaccines & immunotherapeutics · 2024Article
- Community-Engaged Approaches for Improving the Inclusion of Diverse Communities in a Nutrition Clinical Trial.Nutrients · 2024Article
- First, do no harm: a global perspective on diversity and inclusion in clinical trials.Nature reviews. Drug discovery · 2024Article
- Predictors of willingness to participate in COVID-19 clinical trials among Black and Latino adults.Journal of clinical and translational science · 2024Article
- Preparing ethical review systems for emergencies: next steps.BMC medical ethics · 2023Article
- Factors Associated With Enrollment into Inpatient Coronavirus Disease 2019 Randomized Controlled Trials: A Cross-sectional Analysis.Open forum infectious diseases · 2023Article
- Laying the groundwork to make diversity, equity, and inclusion front and center in clinical and translational research.Journal of clinical and translational science · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Introduction: Communities of color have faced disproportionate morbidity and mortality from COVID-19, coupled with historical underrepresentation in US clinical trials, creating challenges for equitable participation in developing and testing a safe and effective COVID-19 vaccine. Methods: To increase diversity, including racial and ethnic representation, in local Los Angeles County NIH-sponsored Phase 3 SARS-CoV-2 vaccine clinical trials, we used deliberative community engagement approaches to form a Community Consultant Panel (CCP) that partnered with trial research teams. Thirteen members were recruited, including expertise from essential workers, community-based and faith-based organizations, or leaders from racial and ethnic minority communities. Results: Working closely with local investigators for the vaccine studies, the CCP provided critical insight on best practices for community trust building, clinical trial participation, and reliable information dissemination regarding COVID-19 vaccines. Modifying recruitment, outreach, and trial protocols led to majority-minority participants (55%-78%) in each of the three vaccine clinical trials. CCP's input led to cultural tailoring of recruitment materials, changes in recruitment messaging, and supportive services to improve trial accessibility and acceptability (transportation, protocols for cultural competency, and support linkages to care in case of an adverse event). Barriers to clinical trial participation unable to be resolved included childcare, requests for after-hours appointment availability, and mobile locations for trial visits. Conclusion: Using deliberative community engagement can provide critical and timely insight into the community-centered barriers to COVID-19 vaccine trial participation, including addressing social determinants of health, trust, clinical trial literacy, structural barriers, and identifying trusted messenger and reliable sources of information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.